BioAtla (NASDAQ:BCAB) Raised to Sell at Wall Street Zen

BioAtla (NASDAQ:BCAB) was upgraded by equities researchers at Wall Street Zen to a “sell” rating in a report released on Saturday.

Several other equities research analysts have also issued reports on BCAB. Citizens Jmp lowered BioAtla from an “outperform” rating to a “market perform” rating in a research report on Wednesday, August 13th. JMP Securities restated a “market perform” rating on shares of BioAtla in a research note on Wednesday, August 13th. Three research analysts have rated the stock with a Hold rating, According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $5.00.

BioAtla Price Performance

Shares of BioAtla stock opened at $0.54 on Friday. BioAtla has a 1 year low of $0.24 and a 1 year high of $2.53. The firm has a market cap of $31.50 million, a PE ratio of -0.49 and a beta of 0.92. The stock has a fifty day moving average price of $0.39 and a 200-day moving average price of $0.39.

BioAtla (NASDAQ:BCAB) last announced its earnings results on Thursday, August 7th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.02). As a group, equities analysts anticipate that BioAtla will post -1.46 EPS for the current fiscal year.

Institutional Investors Weigh In On BioAtla

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Jane Street Group LLC boosted its stake in BioAtla by 204.1% in the 4th quarter. Jane Street Group LLC now owns 149,291 shares of the company’s stock worth $88,000 after purchasing an additional 100,204 shares during the period. Jacobs Levy Equity Management Inc. bought a new position in BioAtla in the 4th quarter worth about $383,000. Tang Capital Management LLC boosted its stake in BioAtla by 57.2% in the 4th quarter. Tang Capital Management LLC now owns 1,374,076 shares of the company’s stock worth $812,000 after purchasing an additional 500,000 shares during the period. Two Sigma Investments LP boosted its stake in BioAtla by 84.0% in the 4th quarter. Two Sigma Investments LP now owns 135,177 shares of the company’s stock worth $80,000 after purchasing an additional 61,725 shares during the period. Finally, Woodline Partners LP bought a new position in BioAtla in the 1st quarter worth about $26,000. 77.23% of the stock is currently owned by institutional investors.

BioAtla Company Profile

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.